This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Knudtson, K. L. Articles by Cole, B. C. Search for Related Content PubMed PubMed Citation Articles by Knudtson, K. L. Articles by Cole, B. C.

 Previous Article  |  Next Article 

Infect. Immun., Dec 1997, 4965-4971, Vol 65, No. 12
Copyright © 1997, American Society for Microbiology

Expression of the superantigen Mycoplasma arthritidis mitogen in Escherichia coli and characterization of the recombinant protein

KL Knudtson, M Manohar, DE Joyner, EA Ahmed and BC Cole
Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City 84132, USA.

Mycoplasma arthritidis mitogen (MAM), is a soluble protein with classical superantigenic properties and is produced by an organism that causes an acute and chronic proliferative arthritis. Unfortunately, the process of obtaining purified MAM from M. arthritidis culture supernatants is extremely time-consuming and costly, and very little material is recovered. Thus, our laboratory has expressed MAM in Escherichia coli by using a protein fusion expression system. The construction and expression of recombinant MAM (rMAM), as well as a comparison of the biological properties of rMAM to those of native MAM, are discussed. Briefly, conversion of the three UGA codons to UGG codons was required to obtain full-length expression and mitogenic activity of rMAM. Antisera to native MAM recognized both rMAM and the fusion protein. The T-cell receptor Vbeta and major histocompatibility complex class II receptor usages by rMAM and the fusion protein were identical to that of native MAM. In addition, the ability to induce suppression and form the superantigen bridge could also be demonstrated with rMAM. Importantly, dose-response experiments indicated that homogeneous native MAM and rMAM were of equal potency. Thus, MAM has been successfully expressed in E. coli, thereby creating a viable alternative to native MAM.

This article has been cited by other articles:

• Li, H., Van Vranken, S., Zhao, Y., Li, Z., Guo, Y., Eisele, L., Li, Y. (2005). Crystal structures of T cell receptor {beta} chains related to rheumatoid arthritis. Protein Sci. 14: 3025-3038 [Abstract] [Full Text]  
• Cole, B. C., Mu, H.-H., Pennock, N. D., Hasebe, A., Chan, F. V., Washburn, L. R., Peltier, M. R. (2005). Isolation and Partial Purification of Macrophage- and Dendritic Cell-Activating Components from Mycoplasma arthritidis: Association with Organism Virulence and Involvement with Toll-Like Receptor 2. Infect. Immun. 73: 6039-6047 [Abstract] [Full Text]  
• Hames, C., Halbedel, S., Schilling, O., Stulke, J. (2005). Multiple-Mutation Reaction: a Method for Simultaneous Introduction of Multiple Mutations into the glpK Gene of Mycoplasma pneumoniae. Appl. Environ. Microbiol. 71: 4097-4100 [Abstract] [Full Text]